natgillin/translations-raw huggingface dataset:
modificeret intent-to-treat-analysesæt (samlet intent-to-treat-analysesæt for stenttrombose) vs. placebo, Log-Rank p-værdi
modified intent to treat analysis set (intent to treat total analysis set for stent thrombosis) vs. placebo; Log-Rank p-value
Modificeret Lactat Ringer’s opløsning, der indeholder standardkomponenterne: vand til injektion,
Modified Lactated Ringer’s Solution containing the standard components: Water for injection, NaCl
Modificeret levende BVDV*-1, ikke-cytopatisk, parentalstamme KE-9: 104.0-106.0 TCID50**
Modified live BVDV*-1, non-cytopathic parent strain KE-9: 104.0–106.0 TCID50**,
Modificeret levende BVDV*-1, ikke-cytopatisk, parentalstamme KE-9: 104.0-106.0 TCID50** Modificeret levende BVDV*-2, ikke-cytopatisk, parentalstamme NY-93: 104.0-106.0 TCID50**
Modified live BVDV*-1, non-cytopathic parent strain KE-9: 104.0–106.0 TCID50**, Modified live BVDV*-2, non-cytopathic parent strain NY-93: 104.0–106.0 TCID50**.
Modificeret levende BVDV*-2, ikke-cytopatisk, parentalstamme NY-93: 104.0-106.0 TCID50**
Modified live BVDV*-2, non-cytopathic parent strain NY-93: 104.0–106.0 TCID50**.
Modificeret LOCF: Post-hoc-analyse, hvor patienterne med virologisk „failure“ eller som afsluttede p.g.a. bivirkninger, blev behandlet som „failures“; for andre „drop-outs“ blev LOCF-metoden (last observation carried forward) brugt.
Modified LOCF: Post-hoc analysis where patients who failed virologically or discontinued for adverse events were treated as failures; for other drop-outs, the LOCF (last observation carried forward) method was applied
Modificeret Total Sharp Score
Modified total sharp score
modificeret udløsning
Aerinaze
Modificeret vaccinia Ankara – Bavarian Nordic levende virus1 ikke mindre end 5 x 107 TCID50 *
Modified Vaccinia Ankara – Bavarian Nordic Live virus1 no less than 5 x 107 TCID50
Modifidieret intent-to-treat
Modified intent-to-treat
Modified Frey’s medium indeholdende phenolrødt og svineserum.
Modified Frey’s medium containing phenol red and swine serum.
Modigraf 0,2 mg granulat til oral suspension
Modigraf 0.2 mg granules for oral suspension
Modigraf 0,2 mg, granulat til oral suspension Modigraf 1 mg, granulat til oral suspension Tacrolimus
Modigraf 0.2 mg, granules for oral suspension Modigraf 1 mg, granules for oral suspension Tacrolimus
Modigraf 1 mg granulat til oral suspension
Modigraf 1 mg granules for oral suspension
Modigraf benyttes til at kontrollere kroppens immunreaktion, således at kroppen kan acceptere det nye transplanterede organ.
Modigraf is used to control your body’s immune response enabling your body to accept the transplanted organ.
Modigraf bør udskrives af læger, som er specielt oplært til at behandle transplantationspatienter, og som har erfaring med brug af lægemidler, som dæmper kroppens immunsystem (immunsuppressiva).
Modigraf should be prescribed by doctors trained to treat transplant patients and experienced in the use of medicines that control the body’s immune system (immunosuppressants).
Modigraf indeholder lactose
Modigraf contains lactose
Modigraf ligner et andet lægemiddel indeholdende tacrolimus, Prograf
Modigraf is similar to another tacrolimus-containing medicine, Prograf or Prograft, which
Modigraf nedsætter kroppens egen forsvarsmekanisme (immunsystemet), som så ikke vil kunne bekæmpe infektioner så godt som normalt.
Modigraf reduces your body’s defence mechanism (immune system), which will not be as good at fighting infections.
Modigraf- kombinationen var dog mere effektiv end de øvrige kombinationer til forebyggelse af organafstødninger, som ikke kunne behandles med corticosteroider.
However, the Modigraf combination was more effective than the other combination at preventing organ rejections that could not be treated by corticosteroids.
Modsat oplevede patienter > 75 år (n = 12) hyppigere alvorlige bivirkninger, udskydelse af dosering, dosisreduktion og seponering end patienter ≤ 75 år (n = 105) ved behandling med ONIVYDE + 5-FU/LV i studiet med pancreasadenokarcinom.
Conversely, patients > 75 years (n=12) experienced more frequent serious adverse reactions, dose delay, dose reduction and discontinuation compared to patients ≤ 75 years (n=105) when treated with ONIVYDE+5-FU/LV in the pancreatic adenocarcinoma study.
Modsat udviste AC-armen højere forekomst af svær anæmi (15,8% mod 8,5%) end AT-armen samt en højere forekomst af svær hjertetoksicitet: kongestivt hjertesvigt (3,8% mod 2,8%), absolut LVEF-nedsættelse ≥ 20% (13,1% mod 6,1%), absolut LVEF- nedsættelse ≥ 30% (6,2% mod 1,1%).
On the other hand, AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease ≥ 20% (13.1% versus 6.1%), absolute LVEF decrease ≥ 30% (6.2% versus 1.1%).
MODSATTE SIDE
REVERSE
modsætning hertil, at øge
PREZISTA/cobicistat may, in contrast,
Modtagelse, opbevaring, anvendelse, overførsel og bortskaffelse skal ske i over- ensstemmelse med de relevante bestemmelser og/eller påkrævede tilladelser fra den kompetente offi- cielle myndighed.
Their receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licences of the competent official organisation.
Modtagelse, opbevaring, anvendelse, overførsel og bortskaffelse skal ske i over- ensstemmelse med de relevante bestemmelser og/eller påkrævede tilladelser fra den kompetente officielle organisation.
Their receipt, storage, use, transfer, and disposal are subject to the regulations and/or appropriate licenses of the competent official organisation.
Modtagelse, opbevaring, anvendelse, overførsel og bortskaffelse skal ske i overensstem- melse med de relevante bestemmelser og/eller påkrævede tilladelser fra den kompetente officielle orga-nisation.
Their receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licences of the competent official organisation.
Modtagelse, opbevaring, brug, transport og bortskaffelse skal udføres i henhold til regulativer og/eller licenser udstedt af offentlige myndigheder.
Its receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licenses of the local competent official organisations.
Modtagere af allogene PBPC’er, som er mobiliseret med filgrastim, fik en signifikant hurtigere hæmatologisk restitution, som medførte et signifikant fald i tiden til ikke-understøttet trombocytrestitution sammenlignet med allogen knoglemarvstransplantation.
Recipients of allogeneic PBPCs mobilised with filgrastim experienced significantly more rapid haematological recovery, leading to a significant decrease in time to unsupported platelet recovery when compared with allogeneic bone marrow transplantation.
Modtagere af allogene perifere blodstamceller mobiliseret med filgrastim
Recipients of allogeneic PBPCs mobilised with filgrastim
Modtagere af hematopoietisk stamcelle transplantation (HSCT), der undergår en høj-dosis immunosuppressiv behandling for graft versus vært sygdom og som har høj risiko for at udvikle invasive svampeinfektioner.
Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.
Modtagere af hematopoietisk stamcelletransplantation (HSCT), der gennemgår en høj-dosis immunsuppressiv behandling for graft versus host-sygdom og som har høj risiko for at udvikle invasive svampeinfektioner.
Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.
Modtagere af hematopoietisk stamcelletransplantation (HSCT), der gennemgår høj-dosis immunsuppressiv behandling for graft versus host-sygdom og som har høj risiko for at udvikle invasive svampeinfektioner.
Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.
Modtagere af hematopoietisk stamcelletransplantation (HSCT), der gennemgår høj-dosis immunsuppressiv behandling for graft versus host-sygdom og som har høj risiko for at udvikle invasive svampeinfektioner.
Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.
Modtagerne af Bexsero omfattede 5.849 spædbørn og børn (under 2 år), 250 børn (2 til 10 år) samt 2.677 unge og voksne.
Among Bexsero recipients, 5849 were infants and children (less than 2 years of age), 250 were children (2 to 10 years of age) and 2677 were adolescents and adults.
Modul 5 – klinisk
Module 5 – Clinical
Mogelijke bijwerkingen
Possible side effects
mogelijke bijwerkingen die niet in deze bijsluiter staan.
not listed in this leaflet.
Mogilska 80, 31-546 Kraków, Polen
Mogilska 80, 31-546 Kraków, Poland
Mogilska 80., Krakow
Mogilska 80,
Molekulær major responskriterier: I den perifere blodreduktion på ≥3 logaritmer i antallet af Bcr- ABL-transkriptioner (målt ved real-time kvantitativ reverse transkriptase PCR assay) over for en standardiserede baseline.
Major molecular response criteria: in the peripheral blood reduction of ≥ 3 logarithms in the amount of Bcr-Abl transcripts (measured by real-time quantitative reverse transcriptase PCR assay) over a standardised baseline.
Molekulær respons**
Molecular response
Molekylær remission ved behandlingsafslutning
Molecular remission at end of treatmentd
MolMedSpA
MolMed SpA
Mometasonfuroat (som monohydrat) 0,9 mg/ml Posaconazol 0,9 mg/ml
Mometasone furoate (as monohydrate) 0.9 mg/mL Posaconazole 0.9 mg/mL
Mometasonfuroat 0,9 mg/ml
Mometasone furoate 0.9 mg/mL
Monensin 32,4 g (svarende til 35,2 g monensinnatrium)
Monensin 32.4 g (equivalent to 35.2 g monensin sodium).
Monensin ændrer den mikroskopiske flora i vommen,
Monensin changes the population of microbes in the
Monepantel er et anthelmintikum, der tilhører klassen af amino-acetonitril-derivater (AAD).
Monepantel is an anthelmintic belonging to the amino-acetonitrile derivative (AAD) class of molecules.
Monepantel- sulfon
Monepantel
Moniterering
Monitoring
Monitorer patienten for forværring af tilstanden.
Monitor patient for worsening of condition.
Monitorer patienten i 6 timer efter den første dosis af Gilenya er blevet administreret for tegn og symptomer på bradykardi, inklusive måling af puls og blodtryk hver time.
Monitor the patient for 6 hours after the first dose of GILENYA has been administered for signs and symptoms of bradycardia, including hourly pulse and blood pressure checks.
Monitorer patienten nøje for toksicitet, og følg vejledningen vedr. modifikation af dosis efter behov.
Monitor patient closely for toxicity and follow dose modification guidance as needed.
Monitorer patienterne for tegn på IMBRUVICA-toksicitet, og følg vejledningen vedr. modifikation af dosis efter behov.
Monitor patients for signs of IMBRUVICA toxicity and follow dose modification guidance as needed.
Monitorer phenytoinkoncentrationen.
Phenytoin/Lamivudine
Monitorer trombocyttallet ugentligt i 4 uger efter, behandlingen med Revolade er stoppet.
Monitor platelet count weekly for 4 weeks following discontinuation of Revolade.
monitoreres efter behov.
be monitored
monitoreres for afatinibrelaterede
ADRs related to afatinib.
monitoreres for voriconazol-
voriconazole is used sequentially
monitoreres klinisk for symptomer på østrogenmangel.
monitored for signs of oestrogen deficiency.
monitoreres nøje og dosis om
monitored and the dose increased
monitoreres nøje.
carefully monitored.
monitoreres nøje.
level carefully monitored.
monitoreres regelmæssigt.
Cholesterol levels should be periodically monitored.
monitoreres tæt for at se, om der
low dose ritonavir, should be
Monitorering
Continuous monitoring
monitorering (ekg osv.)
Not studied.
monitorering (se pkt.
should be done, see section
monitorering af
function, and tacrolimus-associated
Monitorering af anti-Xa-aktivitet bør imidlertid overvejes hos patienter behandlet med lavmolekylært heparin og øget blødningsrisiko (f.eks. patienter med nyreinsufficiens, ældre og patienter med ekstrem legemsvægt) eller aktiv blødning.
However, monitoring of anti-Xa activity should be considered in patients treated with low molecular weight heparin with increased risk of bleeding (e.g., patients with renal impairment, elderly or with extreme body weight) or active bleeding.
Monitorering af anti-Xa-aktiviteten bør imidlertid overvejes hos patienter behandlet med lavmolekylært heparin og øget blødningsrisiko (f.eks. patienter med nyreinsufficiens, ældre og patienter med ekstrem legemsvægt) eller aktiv blødning.
However, monitoring of anti-Xa activity should be considered in patients treated with low molecular weight heparin with increased risk of bleeding (e.g., patients with renal impairment, elderly or with extreme body weight) or active bleeding.
Monitorering af behandlingen - laboratorieundersøgelser
Monitoring of treatment – laboratory tests
Monitorering af binyrebarkfunktion
Monitoring of adrenal function
Monitorering af blod og hjerte
Monitoring of your blood and your heart:
Monitorering af blodkoncentrationen af
Monitoring of
monitorering af ciclosporin
guided by close
Monitorering af diurese
monitoring of urine output
monitorering af diuresen
monitoring of urine output
monitorering af elektrokardiogram og
monitoring of transaminases is
Monitorering af glucose skal intensiveres og dosis af insulin aspart justeres individuelt hos patienter med nedsat nyre- eller leverfunktion.
In patients with renal or hepatic impairment, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.
Monitorering af glucose skal intensiveres og dosis justeres individuelt.
Glucose monitoring is to be intensified and the dose adjusted on an individual basis.
Monitorering af glucose skal intensiveres og insulindosis justeres individuelt (se pkt.
Glucose-monitoring is to be intensified and the insulin dose adjusted on an individual basis (see section 5.2).
Monitorering af infusionsreaktioner hos patienten
Monitoring of the patient for injection/infusion reactions
Monitorering af international normaliseret ratio (INR) anbefales ved administration sammen med og efter ophør af idelalisib-behandling.
It is recommended that the international normalised ratio (INR) be monitored upon co-administration and following ceasing treatment with idelalisib.
Monitorering af intraokulært tryk
Management of intraocular pressure
Monitorering af kreatinkinase anbefales imidlertid.
However monitoring of creatine kinase is recommended.
Monitorering af leverfunktionen
Monitoring of hepatic function
Monitorering af methæmoglobinniveauet
The monitoring of Methaemoglobin level
Monitorering af nyrefunktionen kan
Monitoring of renal function may
Monitorering af nyrefunktionen kan være indiceret, når PREZISTA administreret sammen med lavdosis ritonavir gives i kombination med tenofovir, især hos patienter med underliggende systemisk eller renal sygdom eller hos patienter, der tager nefrotoksiske midler.
with tenofovir, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.
Monitorering af patienter med svært nedsat nyrefunktion
Monitoring of patients with severe renal impairment
monitorering af patienterne
patients is recommended.
Monitorering af saquinavir plasmakoncentrationen anbefales (se pkt.
If the combination is considered necessary, monitoring of the saquinavir plasma levels is strongly encouraged (see section 4.4).
monitorering af serum-kreatinin
monitoring of serum creatinine levels
Monitorering af serumkreatinin bør overvejes hos risikopatienter.
Monitoring of serum creatinine should be considered in at-risk patients.
monitorering af serumkreatinin undladelse af samtidig brug af loop-diuretika Overfølsomhed
monitoring of serum creatinine levels avoidance of concomitant use of loop diuretics Hypersensitivity
monitorering af serumkreatinin undladelse af samtidig brug af loop-diuretika.
monitoring of serum creatinine levels avoidance of concomitant use of loop diuretics.
monitorering af tacrolimus-
dosing interval of
Monitorering af trombocyt- og leucocyttal (WBC)
Platelet and white blood cell (WBC) monitoring
Monitorering af trombocytter
Platelet count monitoring
Monitorering af vitale parametre anbefales, når Flebogamma DIF administreres til pædiatriske patienter.
It is recommended to monitor vital signs when administering Flebogamma DIF to paediatric patients.
monitorering anbefales.
electrocardiogram monitoring is
monitorering anbefales.
recommended.
Monitorering for bivirkninger relateret til oral antikonception udover bivirkninger relateret til voriconazol anbefales.
Monitoring for adverse reactions related to oral contraceptives, in addition to those for voriconazole, is recommended
Monitorering for forhøjet ASAT/ALAT bør overvejes hos patienter med underliggende kronisk hepatitis eller cirrose eller hos patienter, som havde forhøjede aminotransferaser før behandlingen – specielt i de første mange måneders behandling med PREZISTA anvendt i kombination med cobicistat eller lavdosis ritonavir.
Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases, especially during the first several months of PREZISTA used in combination with cobicistat or low dose ritonavir treatment.
Monitorering for forhøjet ASAT/ALAT bør overvejes hos patienter med underliggende kronisk hepatitis eller cirrose eller hos patienter, som havde forhøjede aminotransferaser før behandlingen – specielt i de første mange måneders behandling med PREZISTA/ritonavir.
Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases, especially during the first several months of PREZISTA/ritonavir treatment.
Monitorering for sygdomsaktivitet kan inkludere klinisk undersøgelse, funktionstest eller billeddannende teknikker (f.eks. optisk kohærenstomografi eller fluorescein-angiografi).
Monitoring for disease activity may include clinical examination, functional testing or imaging techniques (e.g. optical coherence tomography or fluorescein angiography).
monitorering for tegn og symptomer på trombose
monitoring for signs and symptoms of thrombosis
Monitorering for tegn på overfølsomhed tilrådes hos patienter med allergi over for thienopyridiner.
Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised..
Monitorering for tegn på overfølsomhed tilrådes hos patienter med allergi over for thienopyridiner.
Monitoring for signs of hypersensitivity in patients with known allergy to thienopyridines is advised.
Monitorering for voriconazol-relaterede bivirkninger anbefales, hvis voriconazol anvendes sekventielt efter fluconazol (se pkt.
Monitoring for voriconazole- associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole (see section 4.5).
Monitorering kan muligvis hjælpe med til at identificere de patienter, som udvikler kardiel dysfunktion.
Monitoring may help to identify patients who develop cardiac dysfunction.
Monitorering og behandling af reaktioner på applikationsstedet
Monitoring and management of application site reactions
monitorering og passende medicinsk behandling i tilfælde af
appropriate medical management in case of
monitorering, da justering af
is recommended, as maintenance
monitorering.
monitoring.
Monitorering:
Monitoring:
Monitoreringer under behandlingen og i 4 år efter den sidste behandling
Monitoring activities during treatment and for 4 years after last treatment
Monitorerings- og behandlingsplanen fastsættes af den behandlende øjenlæge baseret på den enkelte patients respons.
The monitoring and treatment schedule should be determined by the treating physician based on the individual patient’s response.
Monitoreringsstrategi efter seponering af behandlingen med TYSABRI
Monitoring strategy after discontinuation of TYSABRI treatment
Monitoreringstest
Monitoring tests
Monitoring af serumkreatinin bør overvejes hos risikopatienter.
Monitoring of serum creatinine should be considered in at-risk patients.
Monitorér CK- og serumkreatininværdierne ugentligt indtil bedring til baseline.
Monitor CK and serum creatinine levels weekly until resolution to baseline.
Mono terapi
Mono- therapy
Mono- terapi
glycosuria
Mono- terapi
Mono- therapy
Mono/diglycerider af caprylsyre/caprinsyre Polyglycerololeat
Mono/diglycerides of caprylic/capric acid Polyglycerol oleate
Monoaminooxidase-hæmmere (MAO-hæmmere) (til behandling af depression)
Monoamine oxidase inhibitors (MAOI) (used to treat depression)
Monoaminooxidasehæmmere (MAO-hæmmere) (til behandling af depression)
Monoamine oxidase inhibitors (MAOI) (used to treat depression)
Monoaminooxidasehæmmere (MAO-hæmmere) såsom selegilin, rasagilin, moclobamid, phenelzin, isocarboxazid, tranylcypromin (f.eks. til behandling af Parkinsons sygdom eller depression, eller til behandling af en anden tilstand).
Monoamine oxidase (MAO) inhibitors such as selegiline, rasagiline, moclobemide, phenelzine, isocarboxazid, tranylcypromine (e.g. for treatment of Parkinson’s disease or depression, or used for any other condition).
Monoaminooxidasehæmmere (MAO-hæmmere): På grund af risikoen for serotoninsyndrom må duloxetin ikke anvendes sammen med ikke-selektive, irreversible monoaminooxidasehæmmere (MAO-hæmmere) samt i mindst 14 dage efter afbrudt behandling med en MAO-hæmmer.
Monoamine oxidase inhibitors (MAOIs): Due to the risk of serotonin syndrome, duloxetine should not be used in combination with non-selective irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI.
Monoaminooxidasehæmmere (medicin til behandling af depression eller Parkinsons sygdom), såsom phenelzin, selegilin eller rasagilin.
Monoamine oxidase inhibitors (medicines to treat depression or Parkinson’s disease) such as phenelzine, selegiline, or rasagiline.
Monoaminooxidasehæmmere eller (MAO-hæmmere) (mod depression)
Monoamine oxidase inhibitors (MAOI) (used to treat depression).
Monoaminooxidasehæmmere eller (MAOI) (mod depression)
Monoamine oxidase inhibitors (MAOI) (used to treat depression)
Monoaminooxidasehæmmere eller (MAOI) (mod depression)
Monoamine oxidase inhibitors (MAOI) (used to treat depression).
Monoaminooxidasehæmmere eller MAO-hæmmere (mod depression).
Monoamine oxidase inhibitors (MAOI) (used to treat depression).
Monoaminoxidase (MAO) hæmmere - til behandling af depression.
Monoamine oxidase inhibitors (MAOIs) – for depression.
Monoaminoxidasehæmmere (MAO-hæmmere) (til behandling af depression)
Monoamine oxidase inhibitors (MAOI) (used to treat depression)
Monoaminoxidasehæmmere (MAO-hæmmere): De må ikke tage YENTREVE, hvis De tager, eller inden for de sidste 14 dage har taget en antidepressiv medicin kaldet en MAO-hæmmer (monoaminoxidasehæmmer).
Monoamine oxidase inhibitors (MAOIs): You should not take YENTREVE if you are taking or have recently taken (within the last 14 days) an antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Monoaminoxidasehæmmere (MAO-hæmmere): Du må ikke tage Cymbalta sammen med en MAO- hæmmer eller inden for 14 dage efter afsluttet behandling med en MAO-hæmmer.
Monoamine oxidase inhibitors (MAOIs): You should not take Cymbalta if you are taking, or have recently taken (within the last 14 days) another antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Monoaminoxidasehæmmere (MAO-hæmmere): Du må ikke tage Duloxetine Mylan sammen med en MAO-hæmmer eller inden for 14 dage efter afsluttet behandling med en MAO-hæmmer.
Monoamine oxidase inhibitors (MAOIs): You should not take Duloxetine Mylan if you are taking, or have recently taken (within the last 14 days) another antidepressant medicine called a monoamine oxidase inhibitor (MAOI).